MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Country |
 Schweiz |
IPO year |
2016 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
89.9 M |
Market Cap[1] |
$ 4.45 B |
EBITDA (LTM) |
$ -601 M |
P/E (LTM) |
-8.5 |
P/S (LTM) |
1450.21 |
EPS (LTM) |
-6.16 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market |  Canada |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
- | 1.35 % | $ 17.8 M | Nasdaq Capital Market |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 16.88 | -2.43 % | $ 789 M | Nasdaq Global Select Market |  USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.79 | -8.09 % | $ 261 M | Nasdaq Global Market,SPB |  Israel |
 |
Coherus BioSciences
CHRS
|
$ 1.6 | -2.15 % | $ 187 M | Nasdaq Global Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 7.56 | -3.45 % | $ 207 M | Nasdaq Global Market,SPB | Israel |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | Israel |
 |
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Esperion Therapeutics
ESPR
|
$ 3.13 | 0.32 % | $ 651 M | Nasdaq Global Market,SPB | USA |
 |
Exelixis
EXEL
|
$ 50.41 | -1.36 % | $ 13.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Fortress Biotech
FBIO
|
$ 2.43 | 5.65 % | $ 67.8 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
|
Forte Biosciences
FBRX
|
$ 23.1 | -3.57 % | $ 299 M | Nasdaq Capital Market | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 9.76 | 5.63 % | $ 279 M | Nasdaq Capital Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 4.09 | -7.05 % | $ 1.22 B | Nasdaq Global Select Market | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.59 | - | $ 423 M | Nasdaq Global Select Market | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
BioNTech SE
BNTX
|
$ 89.16 | -3.08 % | $ 21.5 B | Nasdaq Global Select Market | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Galectin Therapeutics
GALT
|
$ 2.22 | -5.74 % | $ 142 M | Nasdaq Global Select Market | USA |
 |
Gilead Sciences
GILD
|
$ 130.07 | -1.51 % | $ 162 B | Nasdaq Global Select Market,SPB | USA |
 |
Genmab A/S
GMAB
|
$ 26.8 | -0.37 % | $ 1.73 B | Nasdaq Global Select Market |  Danmark |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.41 | -2.25 % | $ 5.61 M | NYSE American | Israel |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.74 | -0.64 % | $ 5.26 B | Nasdaq Global Select Market |  Spain |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.72 | -1.05 % | $ 32.9 M | Nasdaq Capital Market | Israel |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 29.69 | -0.92 % | $ 799 M | Nasdaq Global Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 21.51 | -0.3 % | $ 2.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.